Moderna (MRNA) Outperforms Broader Market: What You Need to Know

Company Performance - Moderna's stock closed at $27.54, reflecting a +2.53% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.8% [1] - Over the past month, shares of Moderna have increased by 3.11%, while the Medical sector gained 3.12% and the S&P 500 gained 5.12% [1] Upcoming Earnings - Analysts expect Moderna to report an EPS of -$2.97, which is a 10.81% increase from the prior-year quarter [2] - The Zacks Consensus Estimate for revenue is projected at $130.15 million, down 46% from the same period last year [2] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict an EPS of -$9.81 and revenue of $2.08 billion, indicating changes of -10.6% and -35.83% respectively from the previous year [3] - Recent changes to analyst estimates for Moderna suggest a favorable outlook on the company's business health and profitability [3] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 86, placing it in the top 35% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]